The implementation of isoniazid preventive therapy in HIV clinics: The experience from the TB/HIV in Rio (THRio) Study

Betina Durovni, Solange C. Cavalcante, Valeria Saraceni, Vitoria Vellozo, Giselle Israel, Bonnie S. King, Silvia Cohn, Anne Efron, Antonio G. Pacheco, Lawrence Hale Moulton, Richard E Chaisson, Jonathan E Golub

Research output: Contribution to journalArticle

Abstract

Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to antiretroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIV coinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85%) completed therapy and only 20 (1.2%) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87%) than those not yet receiving HAART (79%, P <0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services.

Original languageEnglish (US)
JournalAIDS
Volume24
Issue numberSUPPL. 5
DOIs
StatePublished - Nov 2010

Fingerprint

Isoniazid
Tuberculosis
HIV
Tuberculin Test
Therapeutics
Skin Tests
Highly Active Antiretroviral Therapy
Brazil
Acquired Immunodeficiency Syndrome
Latent Tuberculosis
Cluster Analysis
Teaching
Cohort Studies

Keywords

  • adherence
  • HIV
  • implementation
  • isoniazid preventive therapy
  • tuberculosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

The implementation of isoniazid preventive therapy in HIV clinics : The experience from the TB/HIV in Rio (THRio) Study. / Durovni, Betina; Cavalcante, Solange C.; Saraceni, Valeria; Vellozo, Vitoria; Israel, Giselle; King, Bonnie S.; Cohn, Silvia; Efron, Anne; Pacheco, Antonio G.; Moulton, Lawrence Hale; Chaisson, Richard E; Golub, Jonathan E.

In: AIDS, Vol. 24, No. SUPPL. 5, 11.2010.

Research output: Contribution to journalArticle

Durovni, Betina ; Cavalcante, Solange C. ; Saraceni, Valeria ; Vellozo, Vitoria ; Israel, Giselle ; King, Bonnie S. ; Cohn, Silvia ; Efron, Anne ; Pacheco, Antonio G. ; Moulton, Lawrence Hale ; Chaisson, Richard E ; Golub, Jonathan E. / The implementation of isoniazid preventive therapy in HIV clinics : The experience from the TB/HIV in Rio (THRio) Study. In: AIDS. 2010 ; Vol. 24, No. SUPPL. 5.
@article{a0649d2db1ff4eb19a022ba721e376c1,
title = "The implementation of isoniazid preventive therapy in HIV clinics: The experience from the TB/HIV in Rio (THRio) Study",
abstract = "Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to antiretroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIV coinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85{\%}) completed therapy and only 20 (1.2{\%}) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87{\%}) than those not yet receiving HAART (79{\%}, P <0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services.",
keywords = "adherence, HIV, implementation, isoniazid preventive therapy, tuberculosis",
author = "Betina Durovni and Cavalcante, {Solange C.} and Valeria Saraceni and Vitoria Vellozo and Giselle Israel and King, {Bonnie S.} and Silvia Cohn and Anne Efron and Pacheco, {Antonio G.} and Moulton, {Lawrence Hale} and Chaisson, {Richard E} and Golub, {Jonathan E}",
year = "2010",
month = "11",
doi = "10.1097/01.aids.0000391022.95412.a6",
language = "English (US)",
volume = "24",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 5",

}

TY - JOUR

T1 - The implementation of isoniazid preventive therapy in HIV clinics

T2 - The experience from the TB/HIV in Rio (THRio) Study

AU - Durovni, Betina

AU - Cavalcante, Solange C.

AU - Saraceni, Valeria

AU - Vellozo, Vitoria

AU - Israel, Giselle

AU - King, Bonnie S.

AU - Cohn, Silvia

AU - Efron, Anne

AU - Pacheco, Antonio G.

AU - Moulton, Lawrence Hale

AU - Chaisson, Richard E

AU - Golub, Jonathan E

PY - 2010/11

Y1 - 2010/11

N2 - Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to antiretroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIV coinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85%) completed therapy and only 20 (1.2%) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87%) than those not yet receiving HAART (79%, P <0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services.

AB - Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to antiretroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIV coinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85%) completed therapy and only 20 (1.2%) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87%) than those not yet receiving HAART (79%, P <0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services.

KW - adherence

KW - HIV

KW - implementation

KW - isoniazid preventive therapy

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=78649298939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649298939&partnerID=8YFLogxK

U2 - 10.1097/01.aids.0000391022.95412.a6

DO - 10.1097/01.aids.0000391022.95412.a6

M3 - Article

C2 - 21079428

AN - SCOPUS:78649298939

VL - 24

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - SUPPL. 5

ER -